MedTrace Logo

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent

NCT00589732 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2012-08-08

No results posted yet for this study

Summary

To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.

Conditions

Interventions

DRUG

Valsartan

Valsartan 160mg per day

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Seung-Jung Park

    lead OTHER

Principal Investigators

  • Seung-Jung Park, MD, PhD · Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589732 on ClinicalTrials.gov